Novem Group Acquires New Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Novem Group purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 17,586 shares of the biopharmaceutical company's stock, valued at approximately $841,000.

A number of other institutional investors also recently added to or reduced their stakes in HALO. Voloridge Investment Management LLC acquired a new position in Halozyme Therapeutics in the fourth quarter worth $876,000. Two Sigma Advisers LP bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $282,000. Two Sigma Investments LP lifted its stake in shares of Halozyme Therapeutics by 403.0% in the 4th quarter. Two Sigma Investments LP now owns 247,030 shares of the biopharmaceutical company's stock valued at $11,811,000 after purchasing an additional 197,918 shares during the period. State of Wyoming boosted its position in shares of Halozyme Therapeutics by 35.6% in the 4th quarter. State of Wyoming now owns 14,068 shares of the biopharmaceutical company's stock worth $673,000 after purchasing an additional 3,691 shares during the last quarter. Finally, Steamboat Capital Partners LLC grew its stake in shares of Halozyme Therapeutics by 43.6% during the fourth quarter. Steamboat Capital Partners LLC now owns 249,751 shares of the biopharmaceutical company's stock worth $11,941,000 after purchasing an additional 75,890 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $10,126,499.68. The trade was a 0.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. This represents a 12.95% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,697 shares of company stock worth $696,052. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded down $0.42 during mid-day trading on Tuesday, reaching $54.12. 607,362 shares of the company's stock were exchanged, compared to its average volume of 1,616,643. The firm has a market capitalization of $6.67 billion, a PE ratio of 15.78, a P/E/G ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.51. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The business's fifty day simple moving average is $59.68 and its 200 day simple moving average is $55.75.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.13. The firm had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business's revenue was up 35.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.79 earnings per share. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HALO shares. JPMorgan Chase & Co. boosted their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a research note on Tuesday, May 13th. Finally, Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics presently has an average rating of "Hold" and a consensus price target of $61.90.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.